On Monday, Chimerix Inc (NASDAQ:CMRX)’s shares declined -81% to $6.62.
Chimerix (CMRX), declared that its Phase 3 SUPPRESS trial of brincidofovir in patients undergoing hematopoietic cell transplantation (HCT) did not achieve its primary endpoint for the prevention of clinically noteworthy cytomegalovirus (CMV) infection through Week 24 after transplant.
During the on-treatment period through Week 14 after HCT, fewer patients in the brincidofovir arm had a CMV infection, comprising with the positive antiviral effect of the compound seen in the Phase 2 study. However, during the 10 weeks off treatment from Week 14 to Week 24, there was an enhance in CMV infections in the brincidofovir arm contrast to the control arm. There was also a non-statistically noteworthy enhance in mortality in the brincidofovir arm contrast to the control arm.
Preliminary analysis suggests that the primary endpoint failures in both the prevention of CMV infections and mortality in the brincidofovir arm were driven by confirmed cases of graft-as contrast to-host-disease (GVHD), which resulted in a significantly higher use of corticosteroids than in the control arm. Both GVHD and use of corticosteroids are risk factors for “late” CMV infection that occurs after discontinuation of the antiviral in HCT recipients.
Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral antivirals to address unmet medical needs in the United States. The companys lead compounds comprise brincidofovir (CMX001), an oral nucleotide analog that is in Phase III clinical trial for the prevention of cytomegalovirus (CMV) in adult hematopoietic cell transplant recipients, in addition to to treat adenovirus infection; and CMX157, a nucleotide analog for the treatment of HIV and hepatitis B virus infections. Its preclinical testing product comprises CMX669 for the treatment of BK virus and CMV.
GoPro Inc (NASDAQ:GPRO)’s shares dropped -1.65% to $17.92.
GoPro, Inc. (GPRO) declared The GoPro Channel will be accessible starting recently on the PlayStation®4 (PS4™) and PlayStation®3 (PS3™) systems. The custom designed GoPro Channel app allows PS4 and PS3 owners to stream GoPro content on-demand, browse GoPro cameras and accessories, and more. PlayStation joins GoPro’s growing roster of distribution partners counting Amazon Fire TV, Roku, Comcast Watchable, Sky, Vessel Entertainment, Xbox, LG and Virgin America.
“We want GoPro content and programming to be easily accessible on every platform where our millions of fans spend time,” said Jon Cohen, GoPro’s director, distribution. “There’s a sweet-spot of overlap between PlayStation’s super-engaged audience and the GoPro audience and we’re excited to welcome PlayStation to GoPro’s expanding OTT family.”
Key Features of the GoPro Channel app for PS4 and PS3 systems comprise:
- Activities: Access all the videos related to your favorite activities such as ski, surf and flight
- Improved Search: Search for videos and playlists and watch videos without leaving the search experience
- Playlist Browsing: Navigate to your favorite videos within playlists
- Product Discovery: Watch product videos and learn more about GoPro cameras and accessories
The GoPro Channel app on PS4 and PS3 systems launches in conjunction with an exclusive GoPro video, The 66th Parallel – Discovering Iceland with Ben Brown. The video will be accessible on PS4 and PS3 only, until December 29. After that, check it out on all GoPro platforms.
GoPro, Inc. develops hardware and software solutions to alleviate consumer pain points associated with capturing, managing, sharing, and enjoying engaging content. The company offers HERO line of capture devices, such as cameras; premium accessories, counting battery BacPac, smart remote, and LCD touch BacPac accessories; and mounts comprising equipment-based mounts comprising of helmet, handlebar, roll bar, and grip and tripod mounts that enable consumers to capture content while engaged in a range of activities, in addition to mounts that enable customers to wear the mount on their bodies, such as wrist housings, chest harnesses, and head straps.
Pengrowth Energy Corp (USA) (NYSE:PGH)‘s shares dipped -8.88% to $0.720. The last trading range of Pengrowth Energy Corp (USA) (NYSE:PGH) ranges between $0.72 and $0.79. The EPS of the company stands at $-1.53. The 52-week range shows that the stock reached higher at $3.62 while its lower range is $0.70 in the last 52-weeks. The average volume of the company is at 1.38 million with the Outstanding Shares of 543.03 million. The market capitalization of the company is $432.35 million. The Beta of the company stands at 1.85 with the RSI (Relative Strength Index) of 41.41.
Pengrowth Energy Corporation engages in the acquisition, development, exploration, and production of oil and natural gas assets in the Alberta, British Columbia, Saskatchewan, and Nova Scotia provinces in Canada. It primarily explores for crude oil, bitumen, natural gas, and natural gas liquids.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
